Skip to main content
Erschienen in: Current Atherosclerosis Reports 5/2021

01.05.2021 | Evidence-Based Medicine, Clinical Trials and Their Interpretations (K. Nasir, Section Editor)

Polypills in Cardiovascular Disease Prevention: Mass-Strategy Approach, Precision Medicine, or an Essential Intertwine Between Them?

verfasst von: Giuliano Generoso, Marcio Sommer Bittencourt

Erschienen in: Current Atherosclerosis Reports | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review considers the framework of high-risk vs. population approaches as proposed in the Rose’s axiom within the context of cardiovascular diseases, including its benefits and limitations. We also contextualize the use of precision medicine in primary prevention therapy and contrast that with population approach.

Recent Findings

Although the high-risk strategy aims at individualized care, the complexity of pharmacologic regimens and other limitations reduces its real-life impact. On the other hand, broad population strategies include treatment of a substantial number of low-risk individuals who are unlikely to benefit from treatment. The use of additional strategies to identify those low-risk individuals, instead of targeting at identifying the high-risk population, is and alternative strategy to be considered. Evidence of the potential use of coronary artery calcium score and polypills for this strategy is discussed.

Summary

A more targeted population approach to primary prevention in cardiovascular diseases with the use of polypills and coronary artery calcium score might be considered in a structured mass-strategy approach to risk reduction.
Literatur
3.
Zurück zum Zitat Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028–35.CrossRef Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028–35.CrossRef
4.
Zurück zum Zitat Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125(9):882–7 e1.CrossRef Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125(9):882–7 e1.CrossRef
5.
Zurück zum Zitat Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304–14.CrossRef Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304–14.CrossRef
6.
Zurück zum Zitat Rose G. Strategy of prevention: lessons from cardiovascular disease. Br Med J Clin Res Ed. 1981;282(6279):1847.CrossRef Rose G. Strategy of prevention: lessons from cardiovascular disease. Br Med J Clin Res Ed. 1981;282(6279):1847.CrossRef
7.
Zurück zum Zitat Peters SA, Muntner P, Woodward M. Sex differences in the prevalence of, and trends in, cardiovascular risk factors, treatment, and control in the United States, 2001 to 2016. Circulation. 2019;139(8):1025–35.CrossRef Peters SA, Muntner P, Woodward M. Sex differences in the prevalence of, and trends in, cardiovascular risk factors, treatment, and control in the United States, 2001 to 2016. Circulation. 2019;139(8):1025–35.CrossRef
8.
Zurück zum Zitat Khambhati J, Allard-Ratick M, Dhindsa D, Lee S, Chen J, Sandesara PB, et al. The art of cardiovascular risk assessment. Clin Cardiol. 2018;41(5):677677a.CrossRef Khambhati J, Allard-Ratick M, Dhindsa D, Lee S, Chen J, Sandesara PB, et al. The art of cardiovascular risk assessment. Clin Cardiol. 2018;41(5):677677a.CrossRef
9.
Zurück zum Zitat Thompson C. Roseoseprevention paradox. J Appl Philos. 2018;35(2):242–56.CrossRef Thompson C. Roseoseprevention paradox. J Appl Philos. 2018;35(2):242–56.CrossRef
10.
Zurück zum Zitat Nguyen X-MT, Quaden RM, Wolfrum S, Song RJ, Yan JQ, Gagnon DR, et al. Prevalence of ideal cardiovascular health metrics in the million veteran program. Am J Cardiol. 2018;122(2):347–52.CrossRef Nguyen X-MT, Quaden RM, Wolfrum S, Song RJ, Yan JQ, Gagnon DR, et al. Prevalence of ideal cardiovascular health metrics in the million veteran program. Am J Cardiol. 2018;122(2):347–52.CrossRef
11.
Zurück zum Zitat Mozaffarian D, Afshin A, Benowitz NL, Bittner V, Daniels SR, Franch HA, et al. Population approaches to improve diet, physical activity, and smoking habits: a scientific statement from the American Heart Association. Circulation. 2012;126(12):1514–63.CrossRef Mozaffarian D, Afshin A, Benowitz NL, Bittner V, Daniels SR, Franch HA, et al. Population approaches to improve diet, physical activity, and smoking habits: a scientific statement from the American Heart Association. Circulation. 2012;126(12):1514–63.CrossRef
12.
Zurück zum Zitat Califf RM. Future of personalized cardiovascular medicine. J Am Coll Cardiol. 2018;72(25):3301–9.CrossRef Califf RM. Future of personalized cardiovascular medicine. J Am Coll Cardiol. 2018;72(25):3301–9.CrossRef
13.
Zurück zum Zitat Antman EM, Loscalzo J. Precision medicine in cardiology. Nat Rev Cardiol. 2016;13(10):591.CrossRef Antman EM, Loscalzo J. Precision medicine in cardiology. Nat Rev Cardiol. 2016;13(10):591.CrossRef
14.
Zurück zum Zitat Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. The Lancet. 2009 Apr;373(9672):1341–51. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. The Lancet. 2009 Apr;373(9672):1341–51.
15.
Zurück zum Zitat Patel A, Cass A, Peiris D, Usherwood T, Brown A, Jan S, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol. 2015;22(7):920–30.CrossRef Patel A, Cass A, Peiris D, Usherwood T, Brown A, Jan S, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol. 2015;22(7):920–30.CrossRef
16.•
Zurück zum Zitat Roshandel G, Khoshnia M, Poustchi H, Hemming K, Kamangar F, Gharavi A, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet. 2019;394(10199):672–83 In this study, a polypill strategy was associated with a reduction in cardiovascular events in a randomized clinical trial.CrossRef Roshandel G, Khoshnia M, Poustchi H, Hemming K, Kamangar F, Gharavi A, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet. 2019;394(10199):672–83 In this study, a polypill strategy was associated with a reduction in cardiovascular events in a randomized clinical trial.CrossRef
17.•
Zurück zum Zitat Baumgartner A, Drame K, Geutjens S, Airaksinen M. Does the polypill improve patient adherence compared to its individual formulations? A systematic review. Pharmaceutics. 2020;12(2):190 •BThis meta-analysis demonstrated that a polypill strategy results in improve adherence to treatment in 56 different individual studies.CrossRef Baumgartner A, Drame K, Geutjens S, Airaksinen M. Does the polypill improve patient adherence compared to its individual formulations? A systematic review. Pharmaceutics. 2020;12(2):190 •BThis meta-analysis demonstrated that a polypill strategy results in improve adherence to treatment in 56 different individual studies.CrossRef
18.
Zurück zum Zitat Greenland P. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291(2):210.CrossRef Greenland P. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291(2):210.CrossRef
19.
Zurück zum Zitat Greenland P, Blaha MJ, Budoff MJ, Erbel R, Watson KE. Coronary calcium score and cardiovascular risk. J Am Coll Cardiol. 2018;72(4):434–47.CrossRef Greenland P, Blaha MJ, Budoff MJ, Erbel R, Watson KE. Coronary calcium score and cardiovascular risk. J Am Coll Cardiol. 2018;72(4):434–47.CrossRef
20.
Zurück zum Zitat Peng AW, Mirbolouk M, Orimoloye OA, Osei AD, Dardari Z, Dzaye O, et al. Long-term all-cause and cause-specific mortality in asymptomatic patients with CAC ≥1,000. JACC Cardiovasc Imaging. 2020;13(1):83–93.CrossRef Peng AW, Mirbolouk M, Orimoloye OA, Osei AD, Dardari Z, Dzaye O, et al. Long-term all-cause and cause-specific mortality in asymptomatic patients with CAC ≥1,000. JACC Cardiovasc Imaging. 2020;13(1):83–93.CrossRef
21.
Zurück zum Zitat Bittencourt MS, Blaha MJ, Blankstein R, Budoff M, Vargas JD, Blumenthal RS, et al. Polypill therapy, subclinical atherosclerosis, and cardiovascular events—implications for the use of preventive pharmacotherapy. J Am Coll Cardiol. 2014;63(5):434–43.CrossRef Bittencourt MS, Blaha MJ, Blankstein R, Budoff M, Vargas JD, Blumenthal RS, et al. Polypill therapy, subclinical atherosclerosis, and cardiovascular events—implications for the use of preventive pharmacotherapy. J Am Coll Cardiol. 2014;63(5):434–43.CrossRef
22.
Zurück zum Zitat Wald NJ. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326(7404):1419141.CrossRef Wald NJ. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326(7404):1419141.CrossRef
23.
Zurück zum Zitat Lafeber M, Grobbee DE, Schrover IM, Thom S, Webster R, Rodgers A, et al. Comparison of a morning polypill, evening polypill and individual pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk patients; a randomized crossover trial. Int J Cardiol. 2015;181:193–9.CrossRef Lafeber M, Grobbee DE, Schrover IM, Thom S, Webster R, Rodgers A, et al. Comparison of a morning polypill, evening polypill and individual pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk patients; a randomized crossover trial. Int J Cardiol. 2015;181:193–9.CrossRef
24.
Zurück zum Zitat Mu oz D, Uzoije P, Reynolds C, Miller R, Walkley D, Pappalardo S, et al. Polypill for cardiovascular disease prevention in an underserved population. N Engl J Med. 2019;381(12):1114–23.CrossRef Mu oz D, Uzoije P, Reynolds C, Miller R, Walkley D, Pappalardo S, et al. Polypill for cardiovascular disease prevention in an underserved population. N Engl J Med. 2019;381(12):1114–23.CrossRef
25.
Zurück zum Zitat Lin JK, Moran AE, Bibbins-Domingo K, Falase B, Pedroza Tobias A, Mandke CN, et al. Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study. Lancet Glob Health. 2019;7(10):e1346–58.CrossRef Lin JK, Moran AE, Bibbins-Domingo K, Falase B, Pedroza Tobias A, Mandke CN, et al. Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study. Lancet Glob Health. 2019;7(10):e1346–58.CrossRef
26.
Zurück zum Zitat Jowett S, Barton P, Roalfe A, Fletcher K, Hobbs FDR, McManus RJ, et al. Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high-risk of cardiovascular disease. PloS One. 2017;12(9):e0182625.CrossRef Jowett S, Barton P, Roalfe A, Fletcher K, Hobbs FDR, McManus RJ, et al. Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high-risk of cardiovascular disease. PloS One. 2017;12(9):e0182625.CrossRef
27.
Zurück zum Zitat Gaziano TA, Pandya A, Sy S, Jardim TV, Ogden JM, Rodgers A, et al. Modeling the cost effectiveness and budgetary impact of polypills for secondary prevention of cardiovascular disease in the United States. Am Heart J. 2019;214:77–87.CrossRef Gaziano TA, Pandya A, Sy S, Jardim TV, Ogden JM, Rodgers A, et al. Modeling the cost effectiveness and budgetary impact of polypills for secondary prevention of cardiovascular disease in the United States. Am Heart J. 2019;214:77–87.CrossRef
Metadaten
Titel
Polypills in Cardiovascular Disease Prevention: Mass-Strategy Approach, Precision Medicine, or an Essential Intertwine Between Them?
verfasst von
Giuliano Generoso
Marcio Sommer Bittencourt
Publikationsdatum
01.05.2021
Verlag
Springer US
Erschienen in
Current Atherosclerosis Reports / Ausgabe 5/2021
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-021-00917-4

Weitere Artikel der Ausgabe 5/2021

Current Atherosclerosis Reports 5/2021 Zur Ausgabe

Evidence-Based Medicine, Clinical Trials and Their Interpretations (K. Nasir, Section Editor)

Strengthening the Learning Health System in Cardiovascular Disease Prevention: Time to Leverage Big Data and Digital Solutions

Women and Ischemic Heart Disease (J.M. Peña and F. Lin, Section Editors)

Breast Arterial Calcification: A Potential Biomarker for Atherosclerotic Cardiovascular Disease Risk?

Nutrition (K. Petersen, Section Editor)

Time-Restricted Eating to Improve Cardiovascular Health

Cardiometabolic Disease and Treatment (E. Brinton, Section Editor)

ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.